Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.70 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | HPN | P05981 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12789755 | 0.87 | ELANE (0.57) | ELANECASP3KMT2A | |
| SCHEMBL4113871 | 0.86 | ELANE (0.59) | ELANECASP3TYMSMPOALDH1A1 | |
| SCHEMBL30089873 | 0.86 | ELANE (0.59) | ELANECASP3TYMSMPOALDH1A1 | |
| SCHEMBL12789630 | 0.82 | ELANE (0.56) | ELANECASP3HPNIDO1TDO2 | |
| SCHEMBL4117968 | 0.82 | ELANE (1.00) | ELANEALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3539033 | 0.79 | ELANE (0.70) | ELANETYMSALDH1A1MEN1KMT2A | |
| SCHEMBL12847193 | 0.79 | ELANE (0.70) | ELANEALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12352004 | 0.79 | ELANE (0.70) | ELANEMEN1KMT2A | |
| SCHEMBL1812732 | 0.79 | ELANE (0.70) | ELANETYMSMPOALDH1A1MEN1 | |
| SCHEMBL12758386 | 0.79 | ELANE (0.70) | ELANEALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954731-A | Chalcone derivative containing 4-quinazolinone structure, and preparation method and application thereof | 黔南州烟草公司平塘县分公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-115677803-B | Preparation method of glycoside derivative containing quinazoline structure and composition thereof and application of glycoside derivative and composition for preventing and treating kiwi fruit canker | 贵州理工学院 | 2025-03-28 | — | — | CN | disclosed |
| CN-115521261-B | Preparation method of mercapto-containing quinazolinone and composition thereof, and application of mercapto-containing quinazolinone in resisting kiwi fruit canker | 贵州理工学院 | 2024-04-05 | — | — | CN | disclosed |
| CN-115636795-B | Preparation method of quinazolinone derivative containing thiobenzamide structure and composition thereof, and application of quinazolinone derivative and composition thereof in preventing and treating kiwi fruit canker | 贵州理工学院 | 2024-04-05 | — | — | CN | disclosed |
| CN-115521262-B | Preparation method of quinazolinone containing phenyl and composition thereof, and application of quinazolinone and composition in resisting kiwi fruit canker | 贵州理工学院 | 2024-04-05 | — | — | CN | disclosed |
| CN-115677803-A | Preparation method of glucoside derivative containing quinazoline structure, preparation method of composition of glucoside derivative and application of composition in prevention and treatment of kiwifruit canker | 贵州理工学院 | 2023-02-03 | — | — | CN | disclosed |
| CN-115636795-A | Quinazolinone derivative containing thiobenzamide structure, composition and application of quinazolinone derivative in prevention and treatment of kiwifruit canker | 贵州理工学院 | 2023-01-24 | — | — | CN | disclosed |
| CN-115521261-A | Preparation method of sulfhydryl-containing quinazolinone and composition thereof and application of sulfhydryl-containing quinazolinone in resisting kiwifruit canker | 贵州理工学院 | 2022-12-27 | — | — | CN | disclosed |
| CN-115521262-A | Preparation method of phenyl-containing quinazolinone and composition thereof and application of phenyl-containing quinazolinone in resisting kiwifruit canker | 贵州理工学院 | 2022-12-27 | — | — | CN | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-0552665-A1 | Pyrrolylbenzodiazepinones and medicines containing them | F. HOFFMANN-LA ROCHE AG (CH) | 1993-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | ELANE 2050/4885CASP3 3424/4885HPN 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.